Institut National De La Sante Et De La Recherche Medicale

Université Paris Descartes

Assistance Publique - Hopitaux De Paris (Aphp)

Assistance Publique-Hopitaux De Paris

Université De Paris

Inserm (Institut National De La Sante Et De La Recherche Medicale)

Université Paris Descartes—paris V

Sorbonne Université

Université Paris Diderot-Paris 7

Universite Paris Cité

Veracyte, Inc.

Inserm

Association Gercor

Franck Pages

Jerome Galon

Wolf-Herman Fridman

Gabriela Bindea

Bernhard Mlecnik

Herve Fridman

Bernard Mlecnik

Jérôme Galon

Dewi Vernerey

Julien Taieb

Aurélie Catteau

Fabienne Hermitte

Hervé Fridman

Thierry Andre

Julie Henriques

Jérome Galon

The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.

Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes

The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer.

In vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

A method for assessment of a number or density of immune cells in tumoral tissues comprising the steps consisting in: a. providing one or more immunostained slices of tissue section obtained by an automated slide-staining system by using antibodies binding specifically to antigens (markers) expressed by immune cells. b. proceeding to digitalization of the slides of step a. by high resolution scan capture, whereby a high definition (4.6 &#x3bc;m/pixel or better) digital picture of the slide to be analyzed is obtained, c. detecting the slice of tissue section on the digital picture d. analyzing the slice of tissue section for defining (i) the tumor (CT) and (ii) the invasive margin of the tumor (IM), e. providing a size reference grid with uniformly distributed units having a same surface, said grid being adapted to the size of the tumor to be analyzed, e1. checking the quality of immunostaining, f. detecting and quantifying stained cells of each unit whereby the number or the density of immune cells stained of each unit is assessed.

Method for quantifying immune cells in tumoral tissues and its applications

The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising the steps consisting of i) determining the density of B cells at the invasive margin of the tumor (im) in a tumor tissue sample obtained from said patient, ii) comparing said density with a predetermined reference value and iii) providing a good prognosis when the density of B cells at the invasive margin of the tumor is higher than the predetermined reference value and a poor prognosis when the density of B cells at the invasive margin of the tumor is lower than the predetermined reference value.

Methods for predicting the survival time of a patient suffering from a solid cancer based on density of B cells

The present invention provides methods and kits for the prognosis of survival time of a patient suffering from a cancerous tumor. The method involves quantitating the density of Th17 cells at the center of the tumor and at the invasive margin of the tumor, where low density values at each location indicate a favourable prognosis, high values at each location indicate an unfavourable prognosis, and heterogeneous values at the two locations (one high, one low) indicate an intermediate prognosis.

Methods for predicting the survival time of a patient suffering from a solid cancer

Vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

Growing community of inventors

Paris, France

Franck Pages